Associated Papers
Genotype and clinical phenotype characteristics of MAX germline mutation-associated pheochromocytoma/paraganglioma syndrome.
Lian B et al.
Frontiers in Endocrinology, 2024
Bilateral Pheochromocytoma with Germline MAX Variant without Family History.
Hata S et al.
Clinics and Practice, 2022
35645312 (PubMed )
Supplement: clinpract-12-00035-s001.zip › clinpract-1702561-supplementary.pdf
Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?
Seabrook AJ et al.
The Journal of Clinical Endocrinology and Metabolism, 2021
Integrative genomic and transcriptomic analysis of leiomyosarcoma.
Chudasama P et al.
Nature Communications, 2018
29321523 (PubMed )
Supplement: 41467_2017_2602_MOESM4_ESM.xlsx › 4_Somatic_SNVs
Functional and in silico assessment of MAX variants of unknown significance.
Comino-Méndez I et al.
Journal of Molecular Medicine (berlin, Germany), 2015
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.
Burnichon N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Select a paper to view details